KEY FEATURES
| Full Name | Lipoprotein-associated Phospholipase A2 |
|---|---|
| Synonym | LpPLA2 |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.31-20ng/mL |
| Sensitivity | 0.19ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human LpPLA2 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human LpPLA2. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human LpPLA2 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human LpPLA2, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human LpPLA2. You can calculate the concentration of Human LpPLA2 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES

TYPICAL DATA

Human LpPLA2 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.96 | 1.69 | 8.58 | 0.89 | 1.82 | 7.75 |
| Standard deviation | 0.06 | 0.09 | 0.26 | 0.05 | 0.11 | 0.36 |
| CV(%) | 6.23 | 5.51 | 3.08 | 5.65 | 5.96 | 4.61 |
RECOVERY
The recovery of Human LpPLA2 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 92-104 | 97 |
| EDTA plasma (n=8) | 91-104 | 97 |
| Cell culture media (n=8) | 91-105 | 98 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human LpPLA2 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.

Products associated with LpPLA2 ELISA Kits
| PTGS2 ELISA Kit | publications with LpPLA2 and PTGS2 |
| PLA2G6 ELISA Kit | publications with LpPLA2 and PLA2G6 |
| PLA2G7 ELISA Kit | publications with LpPLA2 and PLA2G7 |
| PTGS1 ELISA Kit | publications with LpPLA2 and PTGS1 |
Pathways associated with LpPLA2 ELISA Kit
| Acyl Chain Remodelling Of PC Pathway | Acyl Chain Remodelling Of PC Pathway |
| Acyl Chain Remodelling Of PE Pathway | Acyl Chain Remodelling Of PE Pathway |
| Acyl Chain Remodelling Of PG Pathway | Acyl Chain Remodelling Of PG Pathway |
| Acyl Chain Remodelling Of PI Pathway | Acyl Chain Remodelling Of PI Pathway |
| Acyl Chain Remodelling Of PS Pathway | Acyl Chain Remodelling Of PS Pathway |
| Arachidonic Acid Metabolism Pathway | Arachidonic Acid Metabolism Pathway |
| Eicosanoid Synthesis Pathway | Eicosanoid Synthesis Pathway |
| Ether Lipid Metabolism Pathway | Ether Lipid Metabolism Pathway |
Diseases associated with LpPLA2 ELISA Kit
| Inflammation | publications with LpPLA2 and Inflammation |
| Colorectal Neoplasms | publications with LpPLA2 and Colorectal Neoplasms |
| Heart Diseases | publications with LpPLA2 and Heart Diseases |
| Atherosclerosis | publications with LpPLA2 and Atherosclerosis |
| Adenocarcinoma | publications with LpPLA2 and Adenocarcinoma |
| Lung Neoplasms | publications with LpPLA2 and Lung Neoplasms |
| Myocardial Ischemia | publications with LpPLA2 and Myocardial Ischemia |
| Necrosis | publications with LpPLA2 and Necrosis |
| Liver Diseases | publications with LpPLA2 and Liver Diseases |
| Hyperplasia | publications with LpPLA2 and Hyperplasia |
Organs/Tissues associated with LpPLA2 ELISA Kit
| Intestine | publications with LpPLA2 and Intestine |
| Lung | publications with LpPLA2 and Lung |
| Heart | publications with LpPLA2 and Heart |
| Stomach | publications with LpPLA2 and Stomach |
| Liver | publications with LpPLA2 and Liver |
| Vascular | publications with LpPLA2 and Vascular |
| Prostate | publications with LpPLA2 and Prostate |
| Muscle | publications with LpPLA2 and Muscle |
| Uterus | publications with LpPLA2 and Uterus |
| Brain | publications with LpPLA2 and Brain |